📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Stemedica

1.1 - Company Overview

Stemedica Logo

Stemedica

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of allogeneic, ischemia-tolerant progenitor cell therapies in clinical development, including itMSCs for ischemic stroke and Alzheimer’s, itNSCs for spinal cord injury, Progenitor Multi-Cell Therapy for stroke, and Progenitor Cell and Protein Combination Therapy for Alzheimer’s; plus BioSmart Technology for manufacturing non-embryonic progenitor cells and StemPro Neural Stem Cells (marketed by ThermoFisher) for research.

Products and services

  • ItMSCs (ischemia-tolerant mesenchymal stem cells): Allogeneic progenitor cell therapy in clinical development intended to treat ischemic stroke and Alzheimer’s disease, characterized by ischemia tolerance
  • BioSmart Technology™: Proprietary platform that produces non-embryonic allogeneic progenitor cells in a low-oxygen, low-tension environment for manufacturing clinical-development cell therapies
  • Progenitor Multi-Cell Therapy: Combination of itMSCs and itNSCs for treating ischemic stroke, uniting ischemia-tolerant mesenchymal and neural progenitor cell components into a single allogeneic therapy.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Stemedica

Immatics Logo

Immatics

HQ: Germany Website
  • Description: Provider of TCR-based cancer immunotherapies and discovery platforms, including ACTengine personalized TCR cell therapy, ACTallo off-the-shelf gamma delta T-cell therapies with TCRs or CARs, TCER bispecific T-cell engaging receptors, and the XPRESIDENT, XCEPTOR, and XCUBE platforms for target identification, TCR discovery/engineering, and AI-powered immunoinformatics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Immatics company profile →
Capstan Therapeutics Logo

Capstan Therapeutics

HQ: United States Website
  • Description: Provider of in vivo mRNA and gene-editing therapeutics powered by its proprietary CellSeeker targeted lipid nanoparticle (tLNP) platform that uses protein binders such as antibodies to deliver mRNA or gene-editing tools to specific cell types. Offerings include CPTX2309, an in vivo CAR-T candidate for autoimmune disorders, immune-cell engineering via mRNA-encoded CARs, and gene-editing delivery to pathogenic cells.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Capstan Therapeutics company profile →
Universal Cells Logo

Universal Cells

HQ: United States Website
  • Description: Provider of nuclease-free rAAV gene editing technology to create universal donor pluripotent and engineered allogeneic stem cells, and cell production for clinical trials. Develops, licenses and commercializes stem cell therapies designed to overcome immune rejection and enable true off-the-shelf therapeutic products using a proprietary genome editing approach.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Universal Cells company profile →
BlueRock Therapeutics Logo

BlueRock Therapeutics

HQ: Canada Website
  • Description: Provider of induced pluripotent stem cell (iPSC) therapies using an industry-leading platform, with programs including bemdaneprocel for Parkinson’s disease, OpCT-001 for primary photoreceptor diseases to restore vision, BR-CM01 to replace damaged heart cells after myocardial infarction or heart failure, and pre-clinical Treg-based therapies for autoimmune disorders; conducts clinical trials to assess safety and efficacy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BlueRock Therapeutics company profile →
BioSenic Logo

BioSenic

HQ: Belgium Website
  • Description: Provider of biopharmaceutical and cell therapy products for bone and osteo-articular diseases, offering ALLOB for bone regeneration; JTA-004 for knee osteoarthritis pain; ArsciCor, an oral arsenic trioxide formulation for chronic graft versus host disease; and ArsciMed, an intravenous arsenic trioxide treatment for autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BioSenic company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Stemedica

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Stemedica

2.2 - Growth funds investing in similar companies to Stemedica

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Stemedica

4.2 - Public trading comparable groups for Stemedica

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Stemedica

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Stemedica

What does Stemedica do?

Stemedica is a provider of allogeneic, ischemia-tolerant progenitor cell therapies in clinical development, including itMSCs for ischemic stroke and Alzheimer’s, itNSCs for spinal cord injury, Progenitor Multi-Cell Therapy for stroke, and Progenitor Cell and Protein Combination Therapy for Alzheimer’s; plus BioSmart Technology for manufacturing non-embryonic progenitor cells and StemPro Neural Stem Cells (marketed by ThermoFisher) for research.

Who are Stemedica's competitors?

Stemedica's competitors and similar companies include Immatics, Capstan Therapeutics, Universal Cells, BlueRock Therapeutics, and BioSenic.

Where is Stemedica headquartered?

Stemedica is headquartered in United States.

How many employees does Stemedica have?

Stemedica has 1,000 employees 🔒.

When was Stemedica founded?

Stemedica was founded in 2010 🔒.

What sector and industry vertical is Stemedica in?

Stemedica is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Stemedica

Who are the top strategic acquirers in Stemedica's sector and industry

Top strategic M&A buyers and acquirers in Stemedica's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Stemedica?

Top strategic M&A buyers groups and sectors for Stemedica include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Stemedica's sector and industry vertical

Which are the top PE firms investing in Stemedica's sector and industry vertical?

Top PE firms investing in Stemedica's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Stemedica's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Stemedica's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Stemedica's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Stemedica include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Stemedica's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Stemedica?

The key public trading comparables and valuation benchmarks for Stemedica include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Stemedica for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Stemedica with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Stemedica's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Stemedica with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Stemedica's' sector and industry vertical?

Access recent funding rounds and capital raises in Stemedica's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Stemedica